Clinical Data Novo Nordisk microRNA drug fluffs its lines in heart failure PharmaphorumA microRNA-targeting drug acquired by Novo Nordisk when it bought Cardior in a $1bn-plus deal has generated disappointing results in heart failure.CardiovascularRead full story pharminent May 11, 2026 (Last updated: May 16, 2026) Pharmaphorum A microRNA-targeting drug acquired by Novo Nordisk when it bought Cardior in a $1bn-plus deal has generated disappointing results in heart failure. Cardiovascular Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Partner’s Bizengri cleared by FDA for ultra-rare cancer days after winning priority voucherNext: Daiichi takes $850M charge, axes facility investment as ADC demand forecast falls Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
